Press Releases

2021.04.06

I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors

Both companies jointly announced that the first patient has been dosed in a phase 1 trial for bispecific antibody TJ-L14B/ABL503.

2021.03.31

I-Mab Announces Upcoming Participation at April Conferences

I-Mab today announced its participation in the following conferences in April.

2021.03.30

I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors

I-Mab and ABL Bio today jointly announced that the U.S. FDA has approved the IND application for initiating phase 1 trial for bispecific antibody TJ-CD4B/ABL111.

2021.03.29

I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates

I-Mab today announced financial results for the full year ended December 31, 2020 and provided key business updates.

2021.03.24

I-Mab to Host 2021 R&D Day

Mandarin session on April 7, 2021 and English session on April 26, 2021 for investors and research analysts.

2021.03.19

I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse

I-Mab today filed a prospectus supplement with the SEC to register 19,050,555 ordinary shares, including ordinary shares represented by ADSs of I-Mab, held by Gaoling Fund, L.P. and YHG Investment, L.P..

2021.03.11

I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting

I-Mab today announced that a poster highlighting the mechanistic differentiation and preclinical research for uliledlimab will be presented at the 2021AACR Annual Meeting taking place virtually April 10 – 15, 2021.

2021.03.10

I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline

I-Mab today announced the signing of two new collaborations that sets in motion a discovery initiative to drive innovation and pipeline growth.

2021.03.03

I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021

Conference Call Scheduled for March 29 at 8:00 a.m. ET with Pre-Registration Required.

2021.02.25

I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin alfa in Pediatric Patients with Growth Hormone Deficiency

I-Mab today announced that the first patient has been dosed in the phase 3 pivotal trial for eftansomatropin alfa as a weekly treatment for pediatric growth hormone deficiency in China.